Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Patients who received the 8 mg weekly dose lost 17.3% and those in the 12 mg group lost 17.5% of body weight, compared to only 1.6% in the placebo group
Ozempic, which has a lower dose of 0.5-2 semaglutide, is FDA-approved for diabetes control, while higher-dose semaglutide, Wegovy, is approved for weight loss
Legal Disclaimer: This product is intended for qualified researchers, laboratories, and institutions conducting in vitro or ex vivo scientific research
It is important to note that PIONEER 3 was a larger trial than PIONEER 12 (1864 participants vs 1441 participants, respectively) and had a longer duration (78 weeks with 5 weeks of follow-up vs 26 weeks with 5 weeks of follow-up, respectively) [18]
US$ 29.21
US$ 20.77
US$ 27.25
